Study of ZD1839 Combined With Irinotecan and Vincristine in Pediatric Patients With Refractory Solid Tumors

NCT00186979 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

34

Enrollment

OTHER

Sponsor class

Conditions

Solid Tumors

Interventions

DRUG: Irinotecan, ZD1839, Vincristine, Cefixime, Cefpodoxime.

Sponsor

St. Jude Children's Research Hospital

Collaborators

[object Object]
[object Object]